EscharEx (5% EX-02 formulation) + Gel Vehicle + Non-surgical standard of care (NSSOC)

Phase 2Completed
0 watching 0 views this week Active
44
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Venous Leg Ulcer

Conditions

Venous Leg Ulcer

Trial Timeline

Dec 2, 2019 → Mar 23, 2022

About EscharEx (5% EX-02 formulation) + Gel Vehicle + Non-surgical standard of care (NSSOC)

EscharEx (5% EX-02 formulation) + Gel Vehicle + Non-surgical standard of care (NSSOC) is a phase 2 stage product being developed by MediWound for Venous Leg Ulcer. The current trial status is completed. This product is registered under clinical trial identifier NCT03588130. Target conditions include Venous Leg Ulcer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT03588130Phase 2Completed

Competing Products

20 competing products in Venous Leg Ulcer

See all competitors
ProductCompanyStageHype Score
EdoxabanDaiichi SankyoPre-clinical
23
DU-176b 15mg + DU-176b 30mg + Enoxaparin sodium 20 mg (=2000IU)Daiichi SankyoPhase 2
52
Edoxaban + Dalteparin + Low molecular weight heparinDaiichi SankyoPhase 3
77
EdoxabanDaiichi SankyoPre-clinical
23
Edoxaban + Standard of CareDaiichi SankyoPhase 3
77
DU-176b + DU-176b + DU-176b + DU-176b + PlaceboDaiichi SankyoPhase 2
52
15mg DU-176b + 30mg DU-176b + FondaparinuxDaiichi SankyoPhase 3
77
DU-176b (edoxaban) + Enoxaparin sodium 20mgDaiichi SankyoPhase 3
77
edoxaban + enoxaparin sodiumDaiichi SankyoPhase 3
77
edoxaban tosylate(DU-176b) + low molecular weight heparin/unfractionated heparin + warfarinDaiichi SankyoPhase 3
77
YM150Astellas PharmaPhase 3
77
YM150Astellas PharmaPhase 3
77
YM150 + enoxaparinAstellas PharmaPhase 2/3
65
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
65
YM150Astellas PharmaPhase 3
77
YM150Astellas PharmaPhase 3
77
YM150 + Placebo + EnoxaparinAstellas PharmaPhase 2/3
65
Dalteparin sodium + Dalteparin sodium/aspirinEisaiPre-clinical
23
dalteparin injectionEisaiPhase 3
77
ONO-7684 + ONO-7684 PlaceboOno PharmaceuticalPhase 1
33